The rotator cuff, a critical component of the shoulder, plays a crucial role in stabilising the joint and facilitating arm movement. When it tears, patients face a decision: to opt for surgical repair or non-surgical treatment. This rotator cuff repair analysis presents a detailed review of both methods, shedding light on their effectiveness, safety, and cost-effectiveness.
Low-to-moderate-certainty evidence suggests that surgical repair does not result in clinically relevant differences in effect compared to non-surgical treatment for degenerative rotator cuff tears. An HTA from the Norwegian institute of public health showed that choosing exclusively non-surgical treatment over surgery can provide up to NOK 81 million in annual cost savings.
Research suggests that there are no clinically relevant differences in effect between surgical and non-surgical treatment. Few serious adverse events were reported, but we are uncertain about the absolute risks. Surgery is the most expensive alternative, and choosing non-surgical treatment over surgery can provide significant cost savings.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
